ORYZF News and Press, Oryzon Genomics S.A. From 04/22/24

Has received “Intention to Grant” from the European Patent Office For the treatment of aggression and social withdrawal MADRID, Spain and CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage bioph...

MADRID, Spain and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the U.S. Food and Dr...

Investing in Oncology Forum 2024 Van Lanschot Kempen Life Sciences Conference Swiss Biotech Day 2024 LSX World Congress MADRID, Spain and BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmace...

Topline data from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD) reported with promising results in secondary endpoints of overall severity and control of agitation/aggression Company planning to request an End-of-Phase II meeting with the FDA to discuss pl...

Keystone Symposia Epigenetic Mechanisms and Cancer Treatment Bio-Neuroscience 17 th Annual European Life Sciences CEO Forum BIO-Europe Spring 2024 MADRID, Spain and BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015...

MADRID, Spain and BOSTON, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today announced that it will host a virtual KOL ev...

Company to host Conference Call and live Webcast on Sunday, January 7, 2024 at 5:30 pm PT. An executive summary of the data to be presented at the 7th Sachs Annual Neuroscience Innovation Forum, on January 7 at 3:30 pm PT, at the Marine’s Memorial Club in San Francisco (USA). R...

7th Sachs Annual Neuroscience Innovation Forum 13rd Annual LifeSci Advisors Corporate Access Event Biotech Showcase-2024 42nd Annual J.P. Morgan Healthcare Conference Invest Securities Biomed Forum 2024 MADRID, Spain and BOSTON, Jan. 03, 2024 (GLOBE NEWSW...

To explore Oryzon’s clinical candidate ORY-4001 in ALS The ALS Association to provide 500,000 USD funding MADRID, Spain and BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging ...

Funding provided by Nice & Green SA, a Swiss private investor This CB Program supersedes the previous one To extend its cash runway and continue the ongoing clinical trials in CNS and oncology Initial execution of €8 million in two tranches of €4 million ...